Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
ALT
STRONG SELLAltimmune, Inc. · Healthcare · United States · $539M · Avg Vol: $12M/d
COMPANY DESCRIPTION
Altimmune, Inc. is a clinical-stage biopharmaceutical company dedicated to developing novel peptide-based therapeutics for chronic diseases, with a primary focus on obesity and liver diseases. The company's pipeline includes differentiated candidates like pemvidutide, a GLP-1/glucagon receptor dual agonist, aiming to address significant unmet medical needs. Its competitive value is intrinsically tied to the clinical efficacy and market potential of its proprietary drug candidates.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | -68.0K | 0.4M | 20.0K | 41.0K | -69.0% | 36.0K | 4.1K | — | -90.0% |
| EPS | -0.46 | -0.60 | -0.50 | -1.00 | — | -0.90 | -0.67 | -0.84 | — |
| Shares | 194.5M | 194.5M | 194.5M | 110.9M | -43.0% | — | — | — | — |
| Debt | 1.1M | 0.7M | 1.7M | 35.7M | 216.7% | 35.8M | — | — | — |
| Equity | 185.3M | 194.1M | 123.5M | 224.9M | 6.7% | — | — | — | — |
| Op CF | -62.6M | -75.8M | -79.8M | -67.5M | — | -71.6M | — | — | — |
| Inv CF | -73.4M | 13.7M | -28.4M | -132.5M | — | — | — | — | — |
| Fin CF | 56.8M | 86.1M | 10.0M | 206.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of ALT are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| ALT | Altimmune, Inc.(you) | $539M | 12 | STRONG SELL |
| EIKN | Eikon Therapeutics, Inc. | $482M | 12 | STRONG SELL |
| VSTM | Verastem, Inc. | $532M | 10 | STRONG SELL |
| DNA | Ginkgo Bioworks Holdings, Inc. | $481M | 15 | STRONG SELL |
| KYTX | Kyverna Therapeutics, Inc. | $450M | 10 | STRONG SELL |
| 0IL8.L | Kyntra Bio, Inc. | $666M | 10 | STRONG SELL |
| CTMX | CytomX Therapeutics, Inc. | $705M | 13 | STRONG SELL |
| SGP | SpyGlass Pharma, Inc. | $685M | 13 | STRONG SELL |
| CABA | Cabaletta Bio, Inc. | $439M | 15 | STRONG SELL |
| ALLO | Allogene Therapeutics, Inc. | $601M | 18 | STRONG SELL |
Peer medians: ROE -25.5% · P/E 27.7x · Gross margin 50.7%